← Back
Data updated: Mar 10, 2026
ARGENX BV
NeurologyOphthalmologyMetabolic
ARGENX BV is a biotechnology company focused on Neurology, Ophthalmology, Metabolic. Key products include VYVGART.
2021
Since
2
Drugs
-
Trials
8
Approved (2yr)
Recent Activity
VYVGART 2025-10-17
Efficacy
VYVGART HYTRULO 2025-10-17
Efficacy
VYVGART HYTRULO 2025-04-10
Efficacy
VYVGART 2024-08-08
Efficacy
VYVGART HYTRULO 2024-08-08
Efficacy
VYVGART 2024-07-24
Labeling
VYVGART HYTRULO 2024-06-21
Efficacy
VYVGART HYTRULO 2024-06-21
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 54%
1 drugs Phase 3: 3 Phase 2: 4 Phase 1: 1
Ophthalmology 24%
0 drugs Phase 3: 3
Metabolic 16%
0 drugs Phase 3: 2
Immunology 4%
0 drugs Phase 2: 1
Oncology 2%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
AbbVie big-pharma
Immunology, Oncology, Neurology, Ophthalmology
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Neurology, Ophthalmology, Immunology
Takeda big-pharma
Immunology, Oncology, Neurology, Metabolic
Novartis big-pharma
Oncology, Immunology, Ophthalmology
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2021-12-17
- Latest
- 2025-10-17
- Applications
- 2